Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Levomepromazine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD3 known ✓ | P35462 | 6/20 | 1.00 |
| ▸ | DRD2 known ✓ | P14416 | 2/20 | 0.51 |
| ▸ | DRD4 known ✓ | P21917 | 1/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 7/20 | 1.00 |
| ▸ | CHRM2 | P08172 | 6/20 | 1.00 |
| ▸ | HTR1A | P08908 | 6/20 | 1.00 |
| ▸ | CHRM1 | P11229 | 6/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 6/20 | 1.00 |
| ▸ | OPRM1 | P35372 | 6/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 6/20 | 1.00 |
| ▸ | ADRA2A | P08913 | 5/20 | 1.00 |
| ▸ | DRD1 | P21728 | 5/20 | 1.00 |
| ▸ | LMNA | P02545 | 4/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 4/20 | 1.00 |
| ▸ | PTGS1 | P23219 | 4/20 | 1.00 |
| ▸ | TBXA2R | P21731 | 3/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 3/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 2/20 | 1.00 |
| ▸ | SLC6A2 | P23975 | 4/20 | 0.74 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.74 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Levomepromazine SCHEMBL29425180 | 1.00 | CYP2D6 (1.00) | CYP2D6CHRM2HTR1ACHRM1ADRA1A | |
| Dextromepromazine SCHEMBL30411640 | 1.00 | CYP2D6 (1.00) | CYP2D6CHRM2HTR1ACHRM1ADRA1A | |
| Levomepromazine SCHEMBL29384983 | 1.00 | CYP2D6 (1.00) | CYP2D6CHRM2HTR1ACHRM1ADRA1A | |
| Levomepromazine SCHEMBL29508092 | 1.00 | CYP2D6 (1.00) | CYP2D6CHRM2HTR1ACHRM1ADRA1A | |
| Levomepromazine SCHEMBL8762418 | 1.00 | CYP2D6 (1.00) | CYP2D6CHRM2HTR1ACHRM1ADRA1A | |
| Levomepromazine SCHEMBL25462 | 1.00 | CYP2D6 (1.00) | CYP2D6CHRM2HTR1ACHRM1ADRA1A | |
| Dextromepromazine SCHEMBL23859840 | 1.00 | CYP2D6 (1.00) | CYP2D6CHRM2HTR1ACHRM1ADRA1A | |
| Levomepromazine SCHEMBL418079 | 0.99 | CYP2D6 (0.98) | CYP2D6CHRM2HTR1ACHRM1ADRA1A | |
| Levomepromazine SCHEMBL29846205 | 0.99 | CYP2D6 (0.98) | CYP2D6CHRM2HTR1ACHRM1ADRA1A | |
| Levomepromazine SCHEMBL1611636 | 0.99 | CYP2D6 (0.98) | CYP2D6CHRM2HTR1ACHRM1ADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0778773-A1 | METHODS FOR TREATING AND/OR PREVENTING ALZHEIMER'S DISEASE USING PHENOTHIAZINES AND/OR THIOXANTHENES | ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY (US) | 1997-06-18 | — | — | EP | claimed |
| WO-1996004915-A1 | METHODS FOR TREATING AND/OR PREVENTING ALZHEIMER'S DISEASE USING PHENOTHIAZINES AND/OR THIOXANTHENES | ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY (US) | 1996-02-22 | — | — | WO | claimed |
| EP-0251904-B1 | PROCESS FOR THE PREPARATION OF ACIDIC LEVOMEPROMAZINE MALEATE | RHONE-POULENC SANTE (FR) | 1990-01-10 | — | — | EP | claimed |
| US-4798895-A | Process for preparing levomepromazine hydrogen maleate | RHONE-POULENC SANTE (FR) | 1989-01-17 | — | — | US | claimed |
| US-20230174581-A1 | PROCESSES AND AGENTS FOR GLAUCOMA | AUFBAU MEDICAL INNOVATIONS LIMITED (IE) | 2023-06-08 | — | — | US | disclosed |
| US-20230013402-A1 | REGENERATING FUNCTIONS AND PHENOTYPES OF CONNECTIVE TISSUE THROUGH NPAS2 SUPPRESSION | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-01-19 | — | — | US | disclosed |
| EP-2743263-B1 | AN IMPROVED PROCESS FOR THE PREPARATION OF LEVOMEPROMAZINE MALEATE | ZCL CHEMICALS LTD (IN) | 2018-01-03 | — | — | EP | disclosed |
| EP-2012793-B1 | USE OF A TRICYCLIC COMPOUND FOR PREPARING A MEDICAMENT FOR TREATING SKELETAL MUSCLE DEGENERATION OF GENETIC ORIGIN | ASS FRANÇAISE CONTRE LES MYOPATHIES (FR) | 2015-04-08 | — | — | EP | disclosed |
| EP-2743263-A1 | An improved process for the preparation of levomepromazine maleate | ZCL Chemicals Ltd. (IN) | 2014-06-18 | — | — | EP | disclosed |
| EP-2743263-A1 | An improved process for the preparation of levomepromazine maleate | ZCL Chemicals Ltd. (IN) | 2014-06-18 | — | — | EP | disclosed |
| US-20130289024-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF FILOVIRUS-MEDIATED DISEASES | U.S. ARMY MEDICAL RESEARCH AND MATERIEL COMMAND | 2013-10-31 | — | — | US | disclosed |
| US-8475804-B2 | Compositions and methods for treatment of filovirus-mediated diseases | U.S. ARMY MEDICAL RESEARCH AND MATERIAL COMMAND (US) | 2013-07-02 | — | — | US | disclosed |
| US-4798895-A | Process for preparing levomepromazine hydrogen maleate | RHONE-POULENC SANTE (FR) | 1989-01-17 | — | — | US | disclosed |
| US-4798895-A | Process for preparing levomepromazine hydrogen maleate | RHONE-POULENC SANTE (FR) | 1989-01-17 | — | — | US | disclosed |
| US-4363800-A | PEPTIDES USEFUL AS ANTITUSSIVES AND AS ANTI-DIARRHDEALS | BURROUGHS WELLCOME CO. (US) | 1982-12-14 | — | — | US | disclosed |
| US-4362717-A | ANTITUSSIVE AGENTS | BURROUGHS WELLCOME CO. (US) | 1982-12-07 | — | — | US | disclosed |
| US-4346083-A | ANTIDIARRHEAL AND ANTITUSSIVE OLIGOPEPTIDES | BURROUGHS WELLCOME CO. (US) | 1982-08-24 | — | — | US | disclosed |
| US-4343795-A | OLIGOPEPTIDES; ANTIDIARRHEA, ANTITUSSIVE | BURROUGHS WELLCOME CO. (US) | 1982-08-10 | — | — | US | disclosed |
| US-4244944-A | OLIGOPEPTIDE OF TYROSINE, METHIONINE (OPTIONALLY OXIDIZED), GLYCINE, NITROPHENYLALANINE, PROLINAMIDE | BURROUGHS WELLCOME CO. (US) | 1981-01-13 | — | — | US | disclosed |
| EP-0002236-A1 | Peptides, their salts, their acid addition salts, pharmaceutical formulations containing them and their use as morphine antagonists and anaesthetics | THE WELLCOME FOUNDATION LIMITED (GB) | 1979-06-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230013402-A1 | REGENERATING FUNCTIONS AND PHENOTYPES OF CONNECTIVE TISSUE THROUGH NPAS2 SUPPRESSION | PER2, NCBP2, NOTCH1 | DRD3 4709/4885DRD2 4481/4885DRD4 4521/4885 |
| US-20230174581-A1 | PROCESSES AND AGENTS FOR GLAUCOMA | RHOA, PDE6C, PDE6A | DRD3 4538/4885DRD2 4792/4885DRD4 4639/4885 |
| US-20130289024-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF FILOVIRUS-MEDIATED DISEASES | FLNA, FLNB, PIGS | DRD3 4854/4885DRD2 4871/4885DRD4 4834/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.